- Meta-analysis is a well-established tool to combine, synthesize and summarize results from independent studies to address one or many questions of interest.
- **Heterogeneity between studies can be due to design, patients' characteristics or comparison** intervention.
- Control risk regression is a meta-analysis about the effectiveness of a treatment including a measure of risk for controls as covariate.
- **Let** *n* be the number of studies, η_i and ξ_i denote unobserved treatment risk and baseline risk, resp., $i = 1, \dots, n$. A basic control risk regression model is (Arends et al., 2000)

Likelihood-Based Inference in Control Risk Regression with Study-Specific Covariates
COTTINGEN **Phus The The Tran 1** Annamaria Guolo ² Annamaria Guolo 2 Cortright of Padova Phuc Thien Tran 1 ¹ Annamaria Guolo² ¹University Medical Center Göttingen ²University of Padova

Background

where τ^2 is the residual variance and σ_{ε}^2 *ξ* is the variance of *ξi* .

$$
\eta_i = \beta_0 + \beta_1 \xi_i + \varepsilon_i, \ \xi_i \sim N\left(\mu_{\xi}, \sigma_{\xi}^2\right), \ \varepsilon_i \sim N\left(0, \tau^2\right),
$$

Observed measures of treatment risk and baseline risk for dichotomous outcome are

$$
\hat{\eta}_i = \log\left(\frac{y_i}{n_{i1} - y_i}\right), \quad \hat{\xi}_i = \log\left(\frac{x_i}{n_{i0} - x_i}\right),
$$

Including covariates other than control risk measure in order to better explain between-study heterogeneity

where ζ_i denotes true values of covariate, μ_ζ and σ_ζ^2 *ζ* are mean and between-studies variance of *ζi* , resp. *ζi* and *ξi* are assumed independent

- **Error-free or error-affected covariates**
- **Likelihood and pseudo-likelihood inference**
- When covariates are summary information, the relationship between covariates and response at the study level might be different from the one at the individual level (aggregation bias, Schmid et al., 2004).
- Covariates can be mismeasured due to quality of instruments or included studies.
- $\hat{\zeta}_i$: observed measure of ζ_i . Thus, the approximate measurement error model is

- where *yi* and *xi* denote the outcomes in the treatment group and in the control group, resp. $\hat{\eta}_i$ and $\hat{\xi}_i$ are observed (summary) versions of η_i and ξ_i , so they prone to measurement errors. Ignoring measurement errors can affect inference, e.g. with the risk of regression dilution (Carroll et al., 2006).
- Ignoring measurement error of $\hat{\eta}_i$ and $\hat{\xi}_i$ may result in more homogeneous treatment effects than really exist, or regression dilution.
- An approximate measurement error model accounts for the measurement error by assuming normality for observed measures given the true ones

$$
\begin{pmatrix} \hat{\eta}_i \\ \hat{\xi}_i \end{pmatrix} \left| \begin{pmatrix} \eta_i \\ \xi_i \end{pmatrix} \sim N_2 \left\{ \begin{pmatrix} \eta_i \\ \xi_i \end{pmatrix}, \begin{pmatrix} s_{\eta_i}^2 & 0 \\ 0 & s_{\xi_i}^2 \end{pmatrix} \right\},\right|
$$

where s_n^2 $\frac{2}{\eta_i} = 1/y_i + 1/\left(n_{i1} - y_i\right)$ and s^2_ξ $\zeta_i = 1/x_i + 1/(n_{i0} - x_i)$ are the within-study variances of η_i and ξ_i , resp.

 $\hat{\eta}_i, \hat{\xi}_i, \hat{\zeta}_i$ \bigwedge^{\top} . \bigwedge^{\top} .

$$
\begin{pmatrix}\n\hat{\eta}_i \\
\hat{\xi}_i\n\end{pmatrix} \sim N_2 \left\{ \begin{pmatrix}\n\beta_0 + \beta_1 \mu_{\xi} \\
\mu_{\xi}\n\end{pmatrix}, \begin{pmatrix}\n\beta_1^2 \sigma_{\xi}^2 + \tau^2 + s_{\eta_i}^2 & \beta_1 \sigma_{\xi}^2 \\
\beta_1 \sigma_{\xi}^2 & \sigma_{\xi}^2 + s_{\xi_i}^2\n\end{pmatrix} \right\}
$$

-
- !) *.*

Objective

$$
\eta_i = \beta_0 + \beta_1 \xi_i + \beta_2 \zeta_i + \varepsilon_i,
$$

$$
\xi_i \sim N\left(\mu_{\xi}, \sigma_{\xi}^2\right), \ \zeta_i \sim N\left(\mu_{\zeta}, \sigma_{\zeta}^2\right), \ \varepsilon_i \sim N\left(0, \tau^2\right),
$$

 $\left(\right)$ *.*

 $\left(\right)$ *.*

Model with Error-Free Covariates

$$
\begin{pmatrix}\n\hat{\eta}_i \\
\hat{\xi}_i\n\end{pmatrix} \sim N_2 \begin{cases}\n\begin{pmatrix}\n\beta_0 + \beta_1 \mu_{\xi} + \beta_2 \zeta_i \\
\mu_{\xi}\n\end{pmatrix},\n\begin{pmatrix}\n\beta_1^2 \sigma_{\xi}^2 + \tau^2 + s_{\eta_i}^2 & \beta_1 \sigma_{\xi}^2 \\
\beta_1 \sigma_{\xi}^2 & \sigma_{\xi}^2 + s_{\xi_i}^2\n\end{pmatrix}\n\end{cases}
$$

!) *.*

■ Sandwich matrix is proposed when using pseudo likelihood approach to account for the risk of misspecification.

Model with Error-Affected Covariates

No. of replicates Scenario $n \in \{10, 2\}$ Parameter Group size *ni*¹ ∼ *ni*⁰ ∼ *U*(15*,* 200)

Bias, standard error, standard deviation, empirical coverage probability, convergence Aim Evaluate performance of likelihood and pseudo likelihood approaches

Consider a meta-analysis of 10 studies, we want to assess the relationship between the risk of mortality in patients getting COVID-19 and schizophrenia, to the baseline risk and other several

Control risk regression with additional covariates is fitted using the naive analysis, likelihood

$$
\begin{pmatrix}\n\hat{\eta}_i \\
\hat{\xi}_i \\
\hat{\zeta}_i\n\end{pmatrix}\n\begin{pmatrix}\n\eta_i \\
\xi_i \\
\zeta_i\n\end{pmatrix}\n\sim N_3 \begin{cases}\n\begin{pmatrix}\n\eta_i \\
\xi_i \\
\zeta_i\n\end{pmatrix}, \Gamma_i =\n\begin{pmatrix}\n\hat{\eta}_i \\
\hat{\zeta}_i \\
\zeta_i\n\end{pmatrix}\n\sim N_3 \begin{cases}\n\beta_0 + \beta_1 \mu_{\xi} + \beta_2 \mu_{\zeta} \\
\mu_{\xi} \\
\mu_{\zeta}\n\end{cases}, \begin{pmatrix}\n\beta_1^2 \sigma_{\xi}^2 + \beta_2^2 \\
\beta_1^2 \sigma_{\zeta}^2 \\
\beta_2 \sigma_{\zeta}^2\n\end{pmatrix}
$$

Proposed Likelihood and Pseudo-Likelihood Approaches

- Let *fi* $\sqrt{ }$ s^2_{ζ} *ζi , sηiζⁱ , sξiζⁱ* \setminus denote the density function of $\sqrt{ }$
- Parameter of interest is $\theta =$ $\sqrt{ }$ $\beta_0, \beta_1, \beta_2, \mu_\xi, \mu_\zeta, \tau^2, \sigma_\xi^2$ *ξ* $, \sigma^2_{\zeta}$ *ζ*
- Components of Γ_i except for s_η^2 *ηi* and $s^2_{\mathcal{E}}$ *ξi* limited information.
- If $\hat{\zeta}_i = \zeta_i + \delta_i, \delta_i \sim N(0, \sigma_{\delta}^2)$ *δ*), only σ_{δ}^2 *δ*

are often unavailable or unable to compute due to

is known and a pseudo-likelihood approach is proposed

$$
pL(\theta) = \prod_{i=1}^{n} f_i\left(\sigma_{\delta}^2, 0, 0\right)
$$

- If $\hat{\zeta}_i$ is summary information, let k be indicator of event, j be indicator of control group, i be study number, $(x_{ijk}, y_{ijk}, z_{ijk})^\top$ be outcome corresponding to $(\xi, \eta, \zeta)^\top$.
- If ζ_i is mean, s^2_ζ *ζi* is known and
- if $\hat{\zeta}_{ijk}$ is unavailable, pseudo-likelihood approach is proposed since $s_{\eta_i\zeta_i}$ and $s_{\xi_i\zeta_i}$ are uncomputable

$$
,0\Big)\ .
$$

$$
pL(\theta) = \prod_{i=1}^{n} f_i (s_{\zeta_i}^2, 0, 0)
$$

otherwise, likelihood approach can be used based on approximation suggested by Bagos (2012)

$$
L(\theta) = \prod_{i=1}^{n} f_i \left(s_{\zeta_i}^2, \frac{1}{n_i} \left(\hat{\zeta}_{i11} - \hat{\zeta}_{i10} \right), \frac{1}{n_i} \left(\hat{\zeta}_{i01} - \hat{\zeta}_{i00} \right) \right).
$$

- If ζ_i is log odds, s^2 $\frac{2}{\zeta_i} = 1/z_i + 1/(n_{i1} + n_{i0} - z_i)$ and
- if $\hat{\zeta}_{ijk}$ is unavailable, pseudo-likelihood approach is proposed since $s_{\eta_i\zeta_i}$ and $s_{\xi_i\zeta_i}$ are uncomputable

$$
pL(\theta) = \prod_{i=1}^{n} f_i\left(s_{\zeta_i}^2, 0, 0\right)
$$

otherwise, likelihood approach can be used based on approximation by Bagos (2012)

$$
L(\theta) = \prod_{i=1}^{n} f_i \left(s_{\zeta_i}^2, \frac{1}{z_i} \left(\frac{z_{i11}}{y_i} - \frac{z_{i10}}{n_{i1} - y_i} \right) - \frac{1}{n_i - z_i} \left(\frac{n_{i11} - z_{i11}}{y_i} - \frac{n_{i10} - z_{i10}}{n_{i1} - y_i} \right),
$$

$$
\frac{1}{z_i} \left(\frac{z_{i01}}{x_i} - \frac{z_{i00}}{n_{i0} - x_i} \right) - \frac{1}{n_i - z_i} \left(\frac{z_{i01} - z_{i01}}{x_i} - \frac{n_{iC0} - z_{i00}}{n_{i0} - x_i} \right).
$$

UNIVERSITÀ DEGLI STUDI DI PADOVA

Schizophrenia Dataset (Pardamean et al., 2022)

- other factors.
- approach and pseudo-likelihood approach.

References

[1] Arends LR et al. (2000). Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. *Stat*

- *Med*, 19 (24), 3497–3518.
-
- [2] Bagos PG et al. (2012). On the covariance of two correlated log-odds ratios. *Stat Med*, 31 (14), 1418-1431. [3] Carroll RJ et al. (2006). Measurement error in nonlinear models: a modern perspective. *CRC*, 2nd Ed.
- [4] Pardamean E et al. (2022). Mortality from coronavirus disease 2019 (COVID-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression. *Gen. Hosp. Psychiatry*, 31 (75), 61-67.
- [5] Schmid CH et al. (2004). Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. *J Clin Epidemiol*, 57 (7), 683-697.

<https://medstat.umg.eu/aktuelles/symposium-meta-analysis-2024/> "Recent Advances in Meta-Analysis" Symposium - Göttingen thien.tran@med.uni-goettingen.de